A new review paper was published in Oncotarget's Volume 14 on August 10, 2023, entitled, "Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies."
Guiding HPV-Linked Cancer Therapy via Tumor Burden Surrogates
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Peripheral surrogates of tumor burden to guide therapeutic strategies for HPV-associated malignancies
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Sensei Biotherapeutics (SNSE) Signs CRAD with NCI to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
PDS Biotech Announces Preliminary Efficacy Achievement in Phase II Combination Trial of PDS0101 Led by the National Cancer Institute · The National Cancer Institute s (NCI) Phase II clinical study of PDS Biotech s PDS0101 for HPV-associated cancers has achieved its preliminary objective response. · Full enrollment for the Phase II trial is triggered by observation of 3 objective responses in continued evaluation of the initial group of 8 patients · Milestone for treatment of HPV-associated cancers NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, announces that its portfolio company PDS Biotechnology Corporation ( PDS ) (Nasdaq: PDSB) has achieved its preliminary objective response for the National Cancer Institute s (NCI) Phase II clinical study of PDS0101 for the treatment of advanced human papill